VYNE Therapeutics Inc.
VYNE
$1.56
$0.0755.07%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 84.00K | 121.00K | 198.00K | 98.00K | 76.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 84.00K | 121.00K | 198.00K | 98.00K | 76.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 84.00K | 121.00K | 198.00K | 98.00K | 76.00K |
| SG&A Expenses | 3.17M | 2.96M | 3.29M | 3.77M | 3.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.85M | 13.21M | 10.59M | 7.48M | 6.91M |
| Operating Income | -12.77M | -13.09M | -10.40M | -7.38M | -6.83M |
| Income Before Tax | -12.01M | -12.16M | -9.40M | -6.24M | -6.15M |
| Income Tax Expenses | 4.00K | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.01M | -12.16M | -9.40M | -6.24M | -6.15M |
| Earnings from Discontinued Operations | -8.00K | -- | -11.00K | -8.00K | -36.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.02M | -12.16M | -9.41M | -6.25M | -6.19M |
| EBIT | -12.77M | -13.09M | -10.40M | -7.38M | -6.83M |
| EBITDA | -12.77M | -- | -- | -- | -6.81M |
| EPS Basic | -0.28 | -0.29 | -0.22 | -0.15 | -0.20 |
| Normalized Basic EPS | -0.18 | -0.18 | -0.14 | -0.09 | -0.12 |
| EPS Diluted | -0.28 | -0.29 | -0.22 | -0.15 | -0.20 |
| Normalized Diluted EPS | -0.18 | -0.18 | -0.14 | -0.09 | -0.12 |
| Average Basic Shares Outstanding | 42.60M | 42.59M | 42.59M | 42.58M | 31.28M |
| Average Diluted Shares Outstanding | 42.60M | 42.59M | 42.59M | 42.58M | 31.28M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
